These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9923821)

  • 1. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
    Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
    Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
    Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
    Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
    Della Torre P; Imondi AR; Bernardi C; Podestà A; Moneta D; Riflettuto M; Mazué G
    Cancer Chemother Pharmacol; 1999; 44(2):138-42. PubMed ID: 10412948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
    Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
    Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
    Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
    Della Torre P; Podestà A; Imondi AR; Moneta D; Sammartini U; Arrigoni C; Terron A; Brughera M
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):355-60. PubMed ID: 11345653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
    Zhang S; Meng T; Liu J; Zhang X; Zhang J
    Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
    Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
    Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
    de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
    Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
    Vaidyanathan S; Boroujerdi M
    Cancer Chemother Pharmacol; 2000; 46(2):93-100. PubMed ID: 10972478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis.
    Zhou L; Sung RY; Li K; Pong NH; Xiang P; Shen J; Ng PC; Chen Y
    Int J Cardiol; 2011 Oct; 152(2):196-201. PubMed ID: 20692056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
    Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
    Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexrazoxane Alleviated Doxorubicin-Induced Nephropathy in Rats.
    Hu H; Xie C; Weng Z; Yu P; Wang Y; Shan L
    Pharmacology; 2022; 107(3-4):206-215. PubMed ID: 35021174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2010 Nov; (558):1-206. PubMed ID: 21383777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 442():1-306. PubMed ID: 12595921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
    Herman EH; Zhang J; Chadwick DP; Ferrans VJ
    Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane does not protect against doxorubicin-induced damage in young rats.
    Héon S; Bernier M; Servant N; Dostanic S; Wang C; Kirby GM; Alpert L; Chalifour LE
    Am J Physiol Heart Circ Physiol; 2003 Aug; 285(2):H499-506. PubMed ID: 12714334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.